–News Direct–

By Faith Ashmore, Benzinga

Over 6.7 million Americans aged 65 and older are living with Alzheimers disease (AD) and this number is predicted to grow to 13.8 million by 2060. AD is the sixth leading cause of death in the U.S. and in 2023, it was projected to cost the U.S. $345 billion. Alzheimer's disease is characterized by a gradual decline in memory, thinking, behavior and social skills; however, a lesser-known subsection of Alzheimers patients despite a prevalence of 40%-80% in the patient population suffer from Agitation in Alzheimers Disease (AAD). AAD is associated with higher admission rates to assisted living facilities, higher use of medications, higher rates of long-term hospitalizations and higher mortality rates for Alzheimers patients. This brings a significant emotional and financial cost to patients and caregivers.

Currently, there is no perfect treatment for AD or ADD. Otsukas (OTC: OSUKF) Rexulti is one of the major medications currently being explored as a potential treatment for Alzheimer's disease. It was originally developed as an atypical antipsychotic to help treat mental health illnesses, and it is believed to work by affecting the activity of certain neurotransmitters in the brain. Due to this, ongoing research is investigating its potential to address the behavioral and psychological symptoms often associated with the condition, such as agitation and aggression, but some concerns are yet to be addressed.

One of the major criticisms of Rexulti is that it carries a black box warning regarding the increased risk of death in elderly patients with dementia-related psychosis. Patients have reported adverse events associated with the drug like restlessness, weight gain and sleepiness. IGC Pharma (AMEX: IGC) is looking to an alternative to existing drugs with its drug, IGC-AD1, which has been specifically designed to target the underlying causes of AAD and aims to fill the gap for a safe and effective therapy.

IGC Pharma began developing IGC-AD1 in 2017, and it was approved by the FDA as an investigational new drug in 2019. IGC-AD1 is designed to target neuroinflammation and dysfunction of the CB1 receptor. This investigational drug contains THC as one of two active pharmaceutical agents. THC is the primary psychoactive compound found in the cannabis plant.

IGC-AD1 is undergoing extensive clinical trials to evaluate its effectiveness and safety in treating Alzheimer's disease. After a successful phase 1 clinical trial that resulted in patent protection in the U.S., the company has moved on to phase 2 trials. The phase 2 clinical trial, begun in 2023, encompasses 20 sites across the United States and Canada. With a target of 146 participants, this trial focuses on determining the efficacy of IGC-AD1 in alleviating agitation in Alzheimer's patients.

The company has just announced the results of an interim analysis of its ongoing phase 2 trial. The main objective of the study is to evaluate the change in AAD over six weeks, utilizing the Cohen Mansfield Agitation Inventory (CMAI). According to IGC Pharma, the study showed that patients who were given IGC-AD1 had a more significant reduction in agitation levels compared to those who were given a placebo, with positive effects being observed as early as week two of the trial.

At the six-week mark, the difference in agitation levels between the IGC-AD1 group and the placebo group was quite noticeable, with an effect size of 0.66 according to Cohen's d measure. The mean difference in the CMAI scores between the active treatment and placebo was -10.45, which indicates a meaningful contrast. Additionally, at the two-week mark, a secondary evaluation showed a positive effect size of 0.79 for IGC-AD1 compared to the placebo.

If IGC-AD1 continues to perform well in clinical trials, it could be an effective, simpler and faster treatment option for patients and importantly, the company is aiming to deliver a product with full approval from the FDA without major black box warnings. The formula as an oral liquid solution also caters to the older population. For millions of Americans who have family members with AD or are worried about developing AD later in life, this drug could provide hope.

Featured photo by Cristina Gottardi on Unsplash.

IGC Pharma Inc. (IGC) is at the forefront of the fight against Alzheimer's disease, developing innovative solutions to address this devastating illness. The company's mission is to transform the landscape of Alzheimer's treatment with a robust pipeline of five promising drug candidates. IGC-AD1 and LMP target the hallmarks of Alzheimer's disease, including neuroinflammation, A plaques, and neurofibrillary tangles. IGC-AD1 is currently undergoing a Phase 2b clinical trial for agitation in dementia associated with Alzheimer's (clinicaltrials.gov, CT05543681). TGR-63 disrupts the progression of Alzheimer's by targeting A plaques. IGC-M3, currently in preclinical development, aims to inhibit the aggregation of A plaques, potentially impacting early-stage Alzheimer's. IGC-1C, also in preclinical stages, targets tau protein and neurofibrillary tangles, representing a forward-thinking approach to Alzheimer's therapy. In addition to its drug development pipeline, IGC Pharma is actively leveraging Artificial Intelligence (AI) for Alzheimer's research. Their AI projects encompass various areas, including clinical trial optimization and early detection of Alzheimer's.

These forward-looking statements are based largely on IGC Pharmas expectations and are subject to several risks and uncertainties, certain of which are beyond IGC Pharmas control. Actual results could differ materially from these forward-looking statements as a result of, among other factors, the Companys failure or inability to commercialize one or more of the Companys products or technologies, including the products or formulations described in this release, or failure to obtain regulatory approval for the products or formulations, where required, or government regulations affecting AI or the AI algorithms not working as intended or producing accurate predictions; general economic conditions that are less favorable than expected; the FDAs general position regarding cannabis- and hemp-based products; and other factors, many of which are discussed in IGC Pharmas U.S. Securities and Exchange Commission ("SEC") filings. IGC Pharma incorporates by reference the human trial disclosures and Risk Factors identified in its Annual Report on Form 10-K filed with the SEC on July 7, 2023, and Quarterly Report on Form 10-Q filed with the SEC on February 14, 2024, as if fully incorporated and restated herein. Considering these risks and uncertainties, there can be no assurance that the forward-looking information contained in this release will occur.

This post contains sponsored content. This content is for informational purposes only and not intended to be investing advice.

Contact Details

Rosalyn Christian

rchristian@imsinvestorrelations.com

Company Website

https://igcpharma.com/

View source version on newsdirect.com: https://newsdirect.com/news/6-7-million-americans-live-with-alzheimers-igc-pharma-believes-they-deserve-treatment-options-without-black-box-warnings-494950963

IGC Pharma, Inc. (IGC)

COMTEX_452115807/2655/2024-05-09T08:45:14